We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04815603
Recruitment Status : Withdrawn (The program priority for execution of this clinical trial changed prior to enrollment of the first patient. The study was not withdrawn due to any safety concerns.)
First Posted : March 25, 2021
Last Update Posted : May 5, 2022
Sponsor:
Information provided by (Responsible Party):
BioAge Labs, Inc.

Brief Summary:
The primary objectives of this study to evaluate the safety, tolerability and efficacy of BGE-117 in the treatment of anemia of aging in participants ≥ 65 years of age.

Condition or disease Intervention/treatment Phase
Anemia Drug: BGE-117 Other: Placebo Phase 2

Detailed Description:

This is a randomized, placebo-controlled, multicenter, double- blind study of BGE-117 administered PO in participants ≥ 65 years of age for the treatment of anemia of aging. Anemia of aging accounts for approximately one-third of anemia in patients over 65 years of age, defined as a suboptimal hemoglobin level due to different underlying characteristics. This study's planned size is 160 evaluable subjects (80 subjects randomized to BGE-117 and 80 subjects randomized to placebo).

After signing informed consent, participants may be Pre-screened for hemoglobin using HemoCue, and subsequently will be screened for study eligibility. Screening will include full physical examination, vital signs, safety and study-related laboratory evaluation, ophthalmic exam, ECG, Wells score for DVT, and clinical outcome assessment. If confirmed that the participant qualifies for this protocol according to listed inclusion and exclusion criteria, participants will be randomized to BGE-117 or placebo, PO, once per day, for a treatment period duration of approximately 12 weeks. Dose adjustments for study medication during the treatment period are made according to a dosing algorithm to achieve and maintain hemoglobin (Hb) within the target range (12.5-13.0 g/dL). Study procedures and assessments are performed at various timepoints during the treatment period per the schedule outlined in the study protocol. Participants will undergo follow-up assessments for approximately 4 weeks after administration of the last dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging
Actual Study Start Date : March 22, 2021
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BGE-117
BGE-117 Capsules (4mg or 12mg) to be taken by mouth once a day for 84 days.
Drug: BGE-117
Active Treatment

Placebo Comparator: Placebo
Placebo Capsules to be taken by mouth once a day for 84 days.
Other: Placebo
Placebo




Primary Outcome Measures :
  1. Hemoglobin [ Time Frame: Day 85 ]
    Change in Hemoglobin compared to baseline


Secondary Outcome Measures :
  1. Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) Score [ Time Frame: Day 29, 57, 85 and Follow-up (up to 120 days) ]
    Improvement in FACIT-Fatigue Score compared to baseline. The FACIT-Fatigue assessment is a 13-item questionnaire that assesses self-reported fatigue and its impact on daily activities and function. The scale is scored from 0 (Not at all) to 4 (Very Much). A lower score is considered improvement and a better outcome.

  2. Hemoglobin [ Time Frame: Day 29, 57, and Follow-up (up to 120 days) ]
    Change in Hemoglobin compared to baseline

  3. Short Physical Performance Battery (SPPB) Score [ Time Frame: Day 29, 57, 85, and Follow-up (up to 120 days) ]
    Change in SPPB Score compared to baseline. The SPPB assessment consists of a Balance Test, a Gait Speed Test, and a Chair Stand Test. Each of the three tests is scored from 0 to 4 points with a composite score from 0 to 12 points. A higher score is considered a better outcome.

  4. 6-minute Walk Test (6MWT) Distance [ Time Frame: Day 29, 57, 85, and Follow-up (up to 120 days) ]
    Change in 6MWT Distance compared to baseline. Increased distance is considered a better outcome.

  5. 36-Item Short Form Survey Instrument (SF-36) [ Time Frame: Day 29, 57, 85, and Follow-up (Up to 120 days) ]
    Change in SF-36 compared to baseline. The SF-36 is a general health status questionnaire to assess patient perception of health in several domains, including physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health over the past 7 days. Each of the categories is scored from 0 to 100. A higher score is considered a better outcome.

  6. BGE-117 Starting Dose Evaluation [ Time Frame: First dose to Day 85 ]
    Evaluate the starting dose of BGE-117 in the treatment of anemia of aging for subjects with eGFR ≥ 60 mL/min/1.73 m2 and subjects with eGFR ≥ 30 and < 60 mL/min/ 1.73 m2

  7. Grip Strength [ Time Frame: Day 29, 57, 85, and Follow-up (Up to 120 days) ]
    Evaluate the change in grip strength measures using the Jamar Hand Dynamometer grip strength test.

  8. Clinical Global Impression (CGI) Measures [ Time Frame: Day 29, 57, 85, and Follow-up (Up to 120 days) ]
    Change in CGI measures compared to baseline. The CGI is a questionnaire-based instrument to assess subjects' progress and treatment response over time. The study will collect the CGI-Change of Condition to measure change in energy level and CGI-Therapeutic Efficacy to assess perceived therapeutic efficacy of treatment. A lower score is considered a better outcome.


Other Outcome Measures:
  1. Analysis of Pharmacokinetic Parameters to Develop a Population Pharmacokinetic Model for BGE-117 (AUC(0-24)/dose) [ Time Frame: Day 1, 29, 57, and 85 ]
    Single blood samples for pharmacokinetic analysis will be collected just prior to first dose and on Days 29, 57 and 85. Time of last dose and time of blood draw will be collected and these data will be used to attempt to develop a population pharmacokinetic model of BGE-117. If possible, AUC(0-24)/dose will be determined. Age, gender and renal function will be explored as covariates.

  2. Analysis of Pharmacokinetic Parameters to Develop a Population Pharmacokinetic Model for BGE-117 (Clearance) [ Time Frame: Day 1, 29, 57, and 85 ]
    Single blood samples for pharmacokinetic analysis will be collected just prior to first dose and on Days 29, 57 and 85. Time of last dose and time of blood draw will be collected and these data will be used to attempt to develop a population pharmacokinetic model of BGE-117. If possible, clearance will be determined. Age, gender and renal function will be explored as covariates.

  3. Analysis of Pharmacokinetic Parameters to Develop a Population Pharmacokinetic Model for BGE-117 (Volume of Distribution) [ Time Frame: Day 1, 29, 57, and 85 ]
    Single blood samples for pharmacokinetic analysis will be collected just prior to first dose and on Days 29, 57 and 85. Time of last dose and time of blood draw will be collected and these data will be used to attempt to develop a population pharmacokinetic model of BGE-117. If possible, volume of distribution will be determined. Age, gender and renal function will be explored as covariates.

  4. Analysis of Pharmacokinetic Parameters to Develop a Population Pharmacokinetic Model for BGE-117 (Half-Life) [ Time Frame: Day 1, 29, 57, and 85 ]
    Single blood samples for pharmacokinetic analysis will be collected just prior to first dose and on Days 29, 57 and 85. Time of last dose and time of blood draw will be collected and these data will be used to attempt to develop a population pharmacokinetic model of BGE-117. If possible, half-life will be determined. Age, gender and renal function will be explored as covariates.

  5. Safety Analyses (Treatment-Emergent Adverse Events) - Number of Events [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Safety analyses will be performed based on the corresponding Safety Set. The number of events of treatment-emergent AEs (TEAEs) will be calculated overall by system organ class, preferred term, and treatment group for each cohort and treatment group. The number of subjects with TEAEs will be further summarized by severity and relationship to the IP.

  6. Safety Analyses (Treatment-Emergent Adverse Events) - Incidence [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Safety analyses will be performed based on the corresponding Safety Set. The incidence of treatment-emergent AEs (TEAEs) will be calculated overall by system organ class, preferred term, and treatment group for each cohort and treatment group. The number and percentage of subjects with TEAEs will be further summarized by severity and relationship to the IP.

  7. Safety Analyses (Treatment-Emergent Adverse Events) - Percentage [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Safety analyses will be performed based on the corresponding Safety Set. The percentage of treatment-emergent AEs (TEAEs) will be calculated overall by system organ class, preferred term, and treatment group for each cohort and treatment group. The percentage of subjects with TEAEs will be further summarized by severity and relationship to the IP.

  8. Safety Analyses (Adverse Events) - Individual Summary [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Adverse events related to IP, AEs leading to withdrawal, SAEs, and deaths will be summarized/listed as part of the overall analysis of safety.

  9. Safety Analyses (Quantitative Safety Data) - Clinical Laboratory Tests [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Clinical laboratory tests (Complete Blood Count, Serum Clinical Chemistries, Coagulation and D-Dimer, Erythropoietin, Hemoglobin Electrophoresis, Inflammation Panel, Iron Panel, Folate and Vitamin B12, Lipid Panel, Thyroid, Urinalysis, Fecal Occult Blood Test) findings will be summarized by treatment group and visit. Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline, if applicable. Frequency counts will be compiled for the classification of qualitative safety data. The baseline for safety data will be defined as the last value prior to the first dose of IP. Potentially clinically important findings will also be summarized or listed.

  10. Safety Analyses (Quantitative Safety Data) - Vital Signs [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Vital signs (systolic and diastolic blood pressure and pulse rate) findings will be summarized by treatment group and visit. Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline, if applicable. Frequency counts will be compiled for the classification of qualitative safety data. The baseline for safety data will be defined as the last value prior to the first dose of IP. Potentially clinically important findings will also be summarized or listed.

  11. Safety Analyses (Quantitative Safety Data) - Ophthalmology Examinations [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Ophthalmology examinations findings will be summarized by treatment group and visit. The assessment will include measurement of best-corrected visual acuity, intraocular pressure, anterior aqueous chamber examination, and fundoscopic examination. Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline, if applicable. Frequency counts will be compiled for the classification of qualitative safety data. The baseline for safety data will be defined as the last value prior to the first dose of IP. Potentially clinically important findings will also be summarized or listed.

  12. Safety Analyses (Quantitative Safety Data) - Wells Score for DVT [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    The Well's Criteria will be used to evaluate for the presence of deep vein thrombosis (DVT) and summarized by treatment group and visit. Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline, if applicable. Frequency counts will be compiled for the classification of qualitative safety data. The baseline for safety data will be defined as the last value prior to the first dose of IP. Potentially clinically important findings will also be summarized or listed.

  13. Safety Analyses (Quantitative Safety Data) - Electrocardiogram (ECG) [ Time Frame: First Dose to Day 85 and Follow-up (Up to 120 days) ]
    Electrocardiogram (ECG) will be performed with heart rate, PR, QRS, and QT (pre-corrected) intervals will be measured and QTcF will be calculated. ECG findings will be summarized by treatment group and visit. Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline, if applicable. Frequency counts will be compiled for the classification of qualitative safety data. The baseline for safety data will be defined as the last value prior to the first dose of IP. Potentially clinically important findings will also be summarized or listed.

  14. Correlation of HemoCue to Central Laboratory Hemoglobin Values [ Time Frame: Pre-Screening to Day 78 ]
    Compare the Hemoglobin values obtained using the HemoCue system to the Hemoglobin values obtained from blood samples tested by the central laboratory.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to voluntarily provide written, signed, and dated informed consent to participate in the study
  • An understanding, ability, and willingness to fully comply with study procedures and restrictions
  • Is 65 years of age or older at the time of Screening (Visit 1)
  • Anemia of Aging defined as a hemoglobin level in the range of ≥ 9.0 g/dL to ≤ 11.5 g/dL (≥ 90 g/L to ≤ 115 g/L) as determined by central laboratory measurement. (Note: For subjects with newly diagnosed anemia, appropriate investigations for the cause of the anemia should be completed according to standard-of-care under the direction of the subject's primary care physician.
  • Weight at Screening (Visit 1) is ≥ 40.0 kg

Exclusion Criteria:

  • History or diagnosis of any of the following:

    • Anemia due to pernicious anemia, thalassemia, sickle cell anemia, sickle trait, or myelodysplastic syndromes
    • Bone-marrow hypoplasia or pure red cell aplasia
    • Androgen deprivation therapy within the previous12 months or radiation treatment for prostate cancer
    • Thyroid-stimulating hormone (TSH) <0.1 mIU/L or >10.0 mIU/L
    • Folic acid and Vitamin B12 levels less than the lower limit of normal range
    • eGFR as measured by Modification of Diet in Renal Disease (MDRD) <30.0 mL/m/1.73 m2
    • Myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack, or pro thrombotic arrhythmia or condition (e.g., untreated atrial fibrillation) within 6 months before Screening or during the Screening (Visit 1).
    • Cancer diagnosis with active or uncertain disease (i.e. active malignancy), or are receiving active treatment within 12 weeks before Screening (Visit 1) (squamous cell or basal cell carcinoma of the skin are excluded from this criterion)
    • Suspected or history of hematologic malignancy. Remote or childhood hematologic malignancies may be permitted as judged by the investigator. Age-related clonal changes in hematopoiesis (e.g., clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of undetermined significance (CCUS)) are permitted as judged by the investigator.
    • Intravenous (IV) iron within 12 weeks before Screening (Visit 1) or during the Screening Period or Treatment Period. Rescue therapy with IV iron is permitted during the Follow-up Period if the subject's hemoglobin is below their baseline level. Note: oral iron supplementation is permitted. The subject must have started treatment with oral iron supplements at least 4 weeks before Screening. The same dose and dosing regimen should be maintained throughout the Screening Period and Treatment Period.
  • Erythropoieisis-stimulating agent (ESA) treatment within 12 weeks before Screening (Visit 1) or during the Screening Period or Treatment Period. Rescue therapy with ESA is permitted during the Follow-up Period if the subject's hemoglobin level is below baseline.
  • History of uncontrolled hypertension including:

    • Difficult-to-control hypertension (unless approved by the investigator and the Medical Monitor)
    • Malignant hypertension (unless approved by the investigator and the Medical Monitor)
    • Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg (confirmed by repeated measurement) within 2 weeks before randomization. Note:

      • Subjects being treated for hypertension should have been on a stable medication and dosing regimen for at least 8 weeks before randomization
      • Subjects may be rescreened after their blood pressure is controlled
  • Evidence of gastrointestinal bleeding within 12 weeks before Screening (Visit 1), as judged by the investigator
  • Blood or plasma donation within 8 weeks before Screening (Visit 1) or at any time during the study period.
  • Class III heart failure, as defined by the New York Heart Association (NYHA) functional classification system
  • QTcF > 500 msec or QTcF > 530 msec in subjects with bundle branch block Note: This evaluation will be done only at Screening (Visit 1); ECG and corresponding intervals and overall interpretation can be mechanically or manually read by an appropriately designated and trained personnel.
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 3 × the upper limit of normal (ULN)
  • Bilirubin > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is < 35%) Note: Bilirubin increases associated with Gilbert's syndrome are permitted.
  • A reported average intake of alcohol of ≥ 80 g/day (i.e., equivalent of 6 cans of beer or 5 shots of hard liquor)
  • Increase in hemoglobin level to the target range (12.5-13.0 g/dL) would pose an unacceptable medical risk to the subject, as judged by the investigator
  • History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product
  • Use of another investigational agent within 30 days or 5 half-lives of the investigational agent; whichever is longer
  • Prior randomization in the current study (BGE-117-201)
  • Any current unstable medical condition that the investigator considers would put the subject at unacceptable risk, affect study compliance, or prevent the understanding of the study's objectives or investigational procedures or possible consequences. This includes:

    • Current, unstable active liver or biliary disease (generally defined by the onset of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, persistent jaundice, or cirrhosis) Note: Stable liver disease (including asymptomatic gallstones, asymptomatic chronic hepatitis B, chronic hepatitis C, or Gilbert's syndrome) is acceptable if the subject otherwise meets entry criteria and the investigator and Sponsor approve entry into the study.
    • Current or relevant history of a medical condition that may require inpatient treatment or make the subject unlikely to complete the study
  • Unable or unwilling to adhere to the contraception requirements specified in the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04815603


Locations
Layout table for location information
Australia, New South Wales
Paratus Clinical Research - Western Sydney
Blacktown, New South Wales, Australia, 248
Emeritus Research Sydney
Botany, New South Wales, Australia, 2019
Northern Beaches Clinical Research
Brookvale, New South Wales, Australia, 2100
Vale Medical Practice
Brookvale, New South Wales, Australia, 2100
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia, 2259
Australia, Queensland
Browns Plains Family (Sonic/IPN)
Browns Plains, Queensland, Australia, 4118
Parkwood Family Practice (Sonic/IPN)
Gold Coast, Queensland, Australia, 4214
AusTrials Taringa
Taringa, Queensland, Australia, 4068
AusTrials Wellers Hill
Tarragindi, Queensland, Australia, 4121
Australia, South Australia
PARC Clinical Research
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Casey Superclinic (Sonic/IPN)
Berwick, Victoria, Australia, 3806
Emeritus Research - Camberwell
Camberwell, Victoria, Australia, 3124
Camberwell Road Medical Practice (Sonic/IPN)
Hawthorn E., Victoria, Australia, 3123
Sponsors and Collaborators
BioAge Labs, Inc.
Layout table for additonal information
Responsible Party: BioAge Labs, Inc.
ClinicalTrials.gov Identifier: NCT04815603    
Other Study ID Numbers: BGE-117-201
First Posted: March 25, 2021    Key Record Dates
Last Update Posted: May 5, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by BioAge Labs, Inc.:
Anemia
BGE-117
BioAge
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Hematologic Diseases